← ANALYST RATINGS · TIPRANKS
Evolus (EOLS): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $15.00, the highest $17.00, the lowest $13.00. The average is +111.3% from the last price of $7.10.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sam Eiber★★★★★★★★★★#4161 · hits 53% · avg +8.6% | BTIG | $13.00 | Buy | +83.1% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | −2.8%next day +4.6% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $9.00 → $7.00−22.2% | Hold | −1.4% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $9.50 → $7.00−26.3% | Hold | −1.4% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $9.00 → $7.00−22.2% | Hold | −1.4% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $8.50 → $7.00−17.6% | Hold | −1.4% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $9.00 → $7.50−16.7% | Hold | +5.6% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $10.00 → $7.00−30.0% | Hold | −1.4% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | — | Buy | — | Reiterated | 16.09.26on TipRanks Sep 17 05:00 | +1.5%next day −0.9% · 5 days −2.0% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $13.00 | Buy | +83.1% | Reiterated | 25.08.26on TipRanks 06:16 | +1.9%next day −2.2% · 5 days +1.7% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $17.00 | Buy | +139.4% | Reiterated | 06.08.26on TipRanks 07:56 | +20.1%next day +1.8% · 5 days +7.0% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | — | Hold | — | Reiterated | 06.08.26on TipRanks 07:11 | +20.1%next day +1.8% · 5 days +7.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Evolus
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.33 at a price of $8.00 (+79.2%); now: $14.33 at $7.10 (+101.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 6 | 5 | 5 | 3 |
| Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Hold | 3 | 2 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.08 to $-0.04). Last quarter: $0.01.
Sales
Next quarter’s sales estimate — $78M (from $77M to $78M). Last quarter: $84M.
Best top-analyst consensus in the sector · Healthcare
About Evolus
- CEO: David Moatazedi
- Employees: 353
- 520 Newport Center Drive, Newport Beach, CA, 92660, US
- www.evolus.com
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Data from the stock’s TipRanks forecast page, read 38 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗